JP2008501042A5 - - Google Patents

Download PDF

Info

Publication number
JP2008501042A5
JP2008501042A5 JP2007527432A JP2007527432A JP2008501042A5 JP 2008501042 A5 JP2008501042 A5 JP 2008501042A5 JP 2007527432 A JP2007527432 A JP 2007527432A JP 2007527432 A JP2007527432 A JP 2007527432A JP 2008501042 A5 JP2008501042 A5 JP 2008501042A5
Authority
JP
Japan
Prior art keywords
pathway
pharmaceutical composition
ige
atopic disease
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007527432A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008501042A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/017514 external-priority patent/WO2005112983A2/en
Publication of JP2008501042A publication Critical patent/JP2008501042A/ja
Publication of JP2008501042A5 publication Critical patent/JP2008501042A5/ja
Withdrawn legal-status Critical Current

Links

JP2007527432A 2004-05-19 2005-05-19 免疫グロブリン産生の調節とアトピー性疾患 Withdrawn JP2008501042A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57240704P 2004-05-19 2004-05-19
PCT/US2005/017514 WO2005112983A2 (en) 2004-05-19 2005-05-19 Modulation of immunoglobulin production and atopic disorders

Publications (2)

Publication Number Publication Date
JP2008501042A JP2008501042A (ja) 2008-01-17
JP2008501042A5 true JP2008501042A5 (enExample) 2008-07-03

Family

ID=35428852

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007527432A Withdrawn JP2008501042A (ja) 2004-05-19 2005-05-19 免疫グロブリン産生の調節とアトピー性疾患

Country Status (15)

Country Link
US (1) US20060024268A1 (enExample)
EP (1) EP1753458A4 (enExample)
JP (1) JP2008501042A (enExample)
KR (1) KR20070014181A (enExample)
CN (1) CN1980698A (enExample)
AU (1) AU2005244942A1 (enExample)
BR (1) BRPI0510996A (enExample)
CA (1) CA2566333A1 (enExample)
EC (1) ECSP067014A (enExample)
IL (1) IL179243A0 (enExample)
MX (1) MXPA06013483A (enExample)
NO (1) NO20065487L (enExample)
RU (1) RU2006138704A (enExample)
WO (1) WO2005112983A2 (enExample)
ZA (1) ZA200609600B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
AU2003251900B2 (en) * 2002-07-15 2008-12-18 President And Fellows Of Harvard College Methods and compositions for modulating T helper (Th) cell development and function
WO2004083249A2 (en) * 2003-03-14 2004-09-30 Wyeth Antibodies against human il-21 receptor and uses therefor
CA2518854A1 (en) * 2003-03-21 2004-10-07 Wyeth Treating immunological disorder using agonists of interleukin-21/interleukin-21 receptor
JP2007506789A (ja) * 2003-09-25 2007-03-22 ザイモジェネティクス， インコーポレイテッド Ｉｌ−２１を用いた自己免疫疾患の治療方法
EP2633866A3 (en) * 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
KR20070057789A (ko) * 2004-08-05 2007-06-07 와이어쓰 인터루킨-21 수용체 활성의 상쇄
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
CN101180315A (zh) * 2005-04-18 2008-05-14 诺和诺德公司 Il-21变体
EP1890723A2 (en) * 2005-06-06 2008-02-27 Novo Nordisk A/S Stabilised il-21 compositions
US7914574B2 (en) * 2005-08-02 2011-03-29 Reva Medical, Inc. Axially nested slide and lock expandable device
EP1960433A2 (en) * 2005-11-28 2008-08-27 Zymogenetics, Inc. Il-21 receptor antagonists
WO2007111714A2 (en) * 2005-11-28 2007-10-04 Zymogenetics, Inc. Il-21 antagonists
AU2007310777A1 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S IL-21 variants
JP2010512769A (ja) * 2006-12-21 2010-04-30 ノヴォ ノルディスク アクティーゼルスカブ Ｉｌ−２１受容体との結合が変化したインターロイキン−２１変異体
EP3103813A1 (en) 2007-12-07 2016-12-14 ZymoGenetics, Inc. Anti-human il-21 monoclonal antibodies
PE20100141A1 (es) * 2008-05-23 2010-02-22 Wyeth Corp Proteina de union al receptor de interleuquina 21
BRPI0912998A2 (pt) * 2008-05-23 2015-10-13 Wyeth Llc métodos de tratamento que utilizam proteínas de ligação do receptor para a interleucina-21
EP2344180A2 (en) * 2008-09-23 2011-07-20 Wyeth LLC Methods for predicting production of activating signals by cross-linked binding proteins
WO2010119307A1 (en) * 2009-04-14 2010-10-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for stimulating antigen-specific t cell responses using accelerated co-cultured dendritic cells
ES2778053T3 (es) 2011-01-18 2020-08-07 Bioniz Llc Composiciones para modular la actividad de la citocina gamma-c
WO2015089217A2 (en) 2013-12-10 2015-06-18 Bionz, Llc Methods of developing selective peptide antagonists
US10077301B2 (en) 2013-06-27 2018-09-18 Monash University IL-21 binding proteins
AU2015367224B2 (en) 2014-12-19 2020-12-10 Monash University IL-21 antibodies
KR102654684B1 (ko) 2015-10-09 2024-04-04 바이오니즈 테라퓨틱스, 아이엔씨. 감마-ｃ-사이토카인 활성의 조정
US11709169B2 (en) * 2017-02-07 2023-07-25 National Jewish Health Lipid abnormalities and association with atopic allergic diseases
US12030936B2 (en) 2019-05-03 2024-07-09 Bioniz Therapeutics, Inc. Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US5179017A (en) * 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) * 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) * 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) * 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) * 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) * 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4510245A (en) * 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4487603A (en) * 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) * 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4596556A (en) * 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4968615A (en) * 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4737323A (en) * 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) * 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0307434B2 (en) * 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US4790824A (en) * 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) * 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
WO1990013327A1 (en) * 1989-04-28 1990-11-15 Riker Laboratories, Inc. Dry powder inhalation device
US5034413A (en) * 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
US5312335A (en) * 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) * 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5399677A (en) * 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
SE9502800D0 (sv) * 1995-08-10 1995-08-10 Astra Ab Disposable inhaler
US20030143204A1 (en) * 2001-07-27 2003-07-31 Lewis David L. Inhibition of RNA function by delivery of inhibitors to animal cells
US7189400B2 (en) * 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US20030212022A1 (en) * 2001-03-23 2003-11-13 Jean-Marie Vogel Compositions and methods for gene therapy
WO2001077171A2 (en) * 2000-04-05 2001-10-18 Zymogenetics, Inc. Soluble zalpha11 cytokine receptors
CA2312142A1 (en) * 2000-06-22 2001-12-22 An-Go-Gen Inc. Injection system for gene delivery
EP1451322B1 (en) * 2001-11-05 2009-09-30 ZymoGenetics, Inc. Il-21 antagonists
EP1572902B1 (en) * 2002-02-01 2014-06-11 Life Technologies Corporation HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
US7556944B2 (en) * 2002-05-03 2009-07-07 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for use in preparing siRNAs
ATE435303T1 (de) * 2002-08-12 2009-07-15 New England Biolabs Inc Verfahren und zusammensetzungen in verbindung mit gen-silencing
WO2004032953A1 (en) * 2002-10-11 2004-04-22 Novo Nordisk A/S Treatment of allergic conditions by use of il 21
WO2004083249A2 (en) * 2003-03-14 2004-09-30 Wyeth Antibodies against human il-21 receptor and uses therefor
CA2518854A1 (en) * 2003-03-21 2004-10-07 Wyeth Treating immunological disorder using agonists of interleukin-21/interleukin-21 receptor
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis

Similar Documents

Publication Publication Date Title
JP2008501042A5 (enExample)
RU2006138704A (ru) Модуляция производства иммуноглобулина и атопические расстройства
Elbaz et al. Losartan, a therapeutic candidate in congenital muscular dystrophy: studies in the dy2J/dy2J mouse
Ultenius et al. Spinal NMDA receptor phosphorylation correlates with the presence of neuropathic signs following peripheral nerve injury in the rat
Truong et al. μ Opioid receptors and analgesia at the site of a peripheral nerve injury
Sergeyev et al. Neuropeptide expression in rats exposed to chronic mild stresses
Riquelme et al. ACE2 is augmented in dystrophic skeletal muscle and plays a role in decreasing associated fibrosis
Dominguez‐Rodriguez et al. Decreased level of melatonin in serum predicts left ventricular remodelling after acute myocardial infarction
Watanabe et al. Expression and regulation of Cav3. 2 T-type calcium channels during inflammatory hyperalgesia in mouse dorsal root ganglion neurons
Zheng et al. Exercise training normalizes enhanced sympathetic activation from the paraventricular nucleus in chronic heart failure: role of angiotensin II
Chen et al. Mechanism of persistent hyperalgesia in neuropathic pain caused by chronic constriction injury
Heller et al. Nest building is impaired in the Ts65Dn mouse model of Down syndrome and rescued by blocking 5HT2a receptors
Roussy et al. Spinal NTS1 receptors regulate nociceptive signaling in a rat formalin tonic pain model
Pineda‐Farias et al. The l‐kynurenine–probenecid combination reduces neuropathic pain in rats
Leinders et al. Up-regulation of spinal microglial Iba-1 expression persists after resolution of neuropathic pain hypersensitivity
Zha et al. Exercise training lowers the enhanced tonically active glutamatergic input to the rostral ventrolateral medulla in hypertensive rats
Elashry et al. Characterisation of connective tissue from the hypertrophic skeletal muscle of myostatin null mice
Xue et al. Nitric oxide stimulates acute pancreatitis pain via activating the NF‐κB signaling pathway and inhibiting the Kappa opioid receptor
Fan et al. The emerging role of neuroimmune interactions in atopic dermatitis and itch
Browne et al. Kappa opioid receptors in the pathology and treatment of major depressive disorder
Gaede et al. Catestatin, a chromogranin A-derived peptide, is sympathoinhibitory and attenuates sympathetic barosensitivity and the chemoreflex in rat CVLM
WO2016138099A1 (en) Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
Huynh et al. Class I HDAC modulates angiotensin II–induced fibroblast migration and mitochondrial overactivity
Anderson et al. Contribution of dynorphin and orexin neuropeptide systems to the motivational effects of alcohol
RS59429B1 (sr) Postupci tretmana poremećaja ciklusa uree